Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

Novavax ($NVAX) has recently seen a decrease in stock value, dropping after announcing Q4 results that missed revenue ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Novavax Inc (NVAX) outlines its strategic focus on partnerships and pipeline expansion while navigating revenue fluctuations ...

Now that Novavax has been added to the revamped COVID vaccines, you'll want to make sure to check on the changes to cost and more.

Diff, varicella-zoster virus, pandemic flu and the triple RSV combination. And finally, we made continued and significant progress in improving Novavax's financial strength. Examples include the ...

Novavax is also progressing well with its preclinical pipeline, which includes vaccines for RSV and H5N1 bird flu. It is also exploring RSV-combination options and new opportunities in diseases ...

Bullish option flow detected in Novavax (NVAX) with 23,789 calls trading, 3x expected, and implied vol increasing over 8 points to 114.25%. Feb-25 8.5 calls and Mar-25 7.5 puts are the most active ...

Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, the company’s earnings beat estimates by 12.64%. The Zacks Consensus ...